• Contact Us
  • News
Dermira Eli Lilly Logo
  • Company
    • About Us
    • Leadership
    • Medical Information
    • Contact Us
  • Our Focus
    • Overview
    • Hyperhidrosis
    • Atopic Dermatitis
    • Helpful Resources
    • Grants & Sponsorships
  • Our Medicines
    • QBREXZA® (glycopyrronium) cloth
    • Authorized Distributors
    • Suppliers
  • R&D
    • Pipeline
    • Lebrikizumab
    • Clinical Trials
    • Early Research Program
    • Medical Information
  • Careers
    • Culture & Values
    • Job Openings
  • Media
    • News Releases
MENU MENU
mobile logo mobile
close-btn
  • Company
    • About Us
    • Leadership
    • Medical Information
    • Contact Us
  • Our Focus
    • Overview
    • Hyperhidrosis
    • Atopic Dermatitis
    • Helpful Resources
    • Grants & Sponsorships
  • Our Medicines
    • QBREXZA® (glycopyrronium) cloth
    • Authorized Distributors
    • Suppliers
  • R&D
    • Pipeline
    • Lebrikizumab
    • Clinical Trials
    • Early Research Program
    • Medical Information
  • Careers
    • Culture & Values
    • Job Openings
  • Media
    • News Releases
  • Contact Us
  • News
FOLLOW US
borderborder

Olumacostat glasaretil, a novel topical sebum inhibitor, in the treatment of acne vulgaris: A Phase IIa, multicenter, randomized, vehicle-controlled study.

  • Investors Overview
  • Stock Information
    • Stock Quote & Chart
    • Historical Price Lookup
    • Investment Calculator
    • Analyst Coverage
  • News Releases
  • Media Resources
  • Events & Presentations
  • Corporate Governance
    • Leadership
    • Board of Directors
    • Committee Composition
    • Documents & Charters
  • Financial Filings
    • SEC Filings
    • Annual Reports
  • Investor FAQs

Company

  • About Us
  • Leadership
  • Medical Information
  • Contact Us

Our Focus

  • Overview
  • Hyperhidrosis
  • Atopic Dermatitis
  • Helpful Resources
  • Grants & Sponsorships

OUR MEDICINES

  • QBREXZA® (glycopyrronium) cloth
  • Authorized Distributors
  • Suppliers

R&D

  • Pipeline
  • Lebrikizumab
  • Clinical Trials
  • Early Research Program
  • Medical Information

CAREERS

  • Culture & Values
  • Job Openings

MEDIA

  • News Releases
FOLLOW US
borderborder
  • Corporate Compliance
  • Privacy Policy
  • Terms of Use
Dermira Eli Lilly Logo
  • Corporate Compliance
  • Privacy Policy
  • Terms of Use
  • Contact Us
  • News
FOLLOW US
borderborder
Dermira Eli Lilly Logo
  • Corporate Compliance
  • Privacy Policy
  • Terms of Use
© 2021 Dermira, Inc., a wholly-owned subsidiary of Eli Lilly and Company. All rights reserved. Dermira and Qbrexza are trademarks of Dermira, Inc.
NP-US-NON-0492

You Are Now Leaving Dermira.com

You’ve clicked on a link for a third-party site, which Dermira, Inc., a wholly-owned subsidiary of Eli Lilly & Company, does not control, influence, or endorse. Dermira is not responsible for any content on this third-party site, including the privacy policy. Click “Continue” to leave or “Return” to return to Dermira.com.

RETURN
CONTINUE
NP-US-NON-0492